Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Patients with < 3-log reduction in the RUNX1-RUNX1T1 transcript level after the second consolidation therapy (defined as MRD-H) had a significantly lower 2-year RFS rate than patients with ≥ 3-log reduction (MRD-L) (P = .017).
|
31364309 |
2019 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Areas covered: Available techniques include multi-color flow cytometry (MFC) of leukemia associated immunophenotypes (LAIP), quantitative reverse transcriptase polymerase chain reaction (QRT-PCR) for detecting fusion and mutated genes (RUNX1-RUNX1T1, CBFB-MYH11, and NPM1), overexpression of genes such as WT1, and next generation sequencing (NGS) for MRD.
|
28475434 |
2017 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We identified that poor-risk karyotype showed very poor outcome after auto-HCT, and then analyzed 85 patients with good to intermediate-risk molecular cytogenetics with available molecular study results and markers for minimal residual disease (MRD) such as WT1 and core-binding factor (CBF) associated MRD (ie, AML1/ETO and CBFβ/MYH11).
|
28089879 |
2017 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We asked whether minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels could identify allogeneic hematopoietic stem cell transplantation (allo- HSCT) t(8;21) (q22;q22) acute myeloid leukemia patients who are at high risk for relapse, together with the impact of c-KIT mutations.
|
25082877 |
2014 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
RUNX1-RUNX1T1 MRD levels measured on DNA and RNA were strongly correlated (r = 0.8, P < 0.0001).
|
24616160 |
2014 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
To determine the prognostic significance of the detection of the minimal residual disease (MRD) in children with AML1/ETO AML, we compared the results of reverse-transcription polymerase chain reaction (RT-PCR) and quantitative reverse-transcription polymerase chain reaction (RQ-PCR).
|
24920269 |
2014 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our study shows that both qualitative and quantitative detection of AML1/ETO have prognostic value in MRD monitoring.
|
23613269 |
2013 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We aimed to improve the outcome of t(8;21) acute myeloid leukemia (AML) in the first complete remission (CR1) by applying risk-directed therapy based on minimal residual disease (MRD) determined by RUNX1/RUNX1T1 transcript levels.
|
23535063 |
2013 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Most sensitive methodology to detect MRD is molecular polymerase chain reaction (PCR) but its applicability is restricted to AML with leukemia-specific molecular targets (e.g.AML1-ETO, CBFB-MYH11, MLL, FLT-3).
|
22196957 |
2012 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In core binding factor (CBF) acute myeloid leukaemia (AML), realtime quantitative PCR is useful to quantify the fusion transcript ratio (CBFβ-MYH11 and AML1-ETO, in case of inv(16) and t(8;21) respectively) in peripheral blood and bone marrow during the courses of chemotherapy, in order to monitor minimal residual disease (MRD).
|
22871474 |
2012 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Comparative monitoring of MRD by RQ-PCR for the Wilms' tumor gene 1(WT1) or specific translocation markers demonstrated that BAALC had similar kinetics as WT1, AML1/ETO and minor BCR/ABL, but not PML/RARA.
|
20376583 |
2010 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
To examine the prognostic significance of minimal residual disease (MRD) in t(8;21) acute myeloid leukemia (AML), 96 bone marrow samples from 26 Japanese patients in complete remission (CR) were analyzed regarding the RUNX1/MTG8 transcript using real-time reverse transcriptase polymerase chain reaction assay.
|
18553224 |
2008 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We quantified MRD at various time points during and after therapy by real-time reverse transcriptase polymerase chain reaction (RT-PCR) for AML1/MTG8 and CBFB/MYH11 in 37 patients with CBF leukemias treated within a multicenter trial.
|
14645432 |
2003 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
|
12764380 |
2003 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Since AML1/MTG8 fusion transcripts remain detectable by RT-PCR in t(8;21) AML patients in long-term hematological remission, quantitative assessment of AML1/MTG8 transcripts is necessary for the monitoring of minimal residual disease (MRD) in these patients.
|
10673753 |
2000 |
Neoplasm, Residual
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The results suggest that we may easily monitor MRD in patients with t(8;21) AML through quantitative analysis of AML1-ETO transcripts in blood samples.
|
10776697 |
2000 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We hypothesized that the overexpression of the MTG8 gene in t(8;21) AML cells could act as a possible tumour antigen, which might be able to induce the immune-mediated suppression of the expansion of MRD.
|
11122105 |
2000 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here we studied minimal residual disease (MRD) of patients with acute myeloid leukemia (AML) who have PML/RAR alpha or AML1/ETO as well as the phenotypic analysis of lymphocyte subsets involved in antitumor immunity.
|
9643569 |
1998 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The genes PML and AML1, and ETO were examined in normal hematopoietic progenitors and their fusions proteins, PML/RAR alpha and AML1/ETO, measured in patients in clinical remission, and important data were presented concerning these proteins and measurement of minimal residual disease.
|
9260053 |
1997 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Recently, we have developed a quantitative assay using competitive reverse transcriptase polymerase chain reaction that estimates the number of AML1/ETO transcripts in t(8;21) acute myelogenous leukemia (AML), in order to determine the degree of leukemic cell contamination in PBSC harvests, and to monitor minimal residual disease (MRD) quantitatively in patients with t(8;21) AML.
|
9130615 |
1997 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The chimaeric AML1/ETO transcript is useful for the detection of minimal residual disease (MRD).
|
8857943 |
1996 |
Neoplasm, Residual
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Using this method, we have tested sequential samples from 13 patients to monitor minimal residual disease and were able to show a significant increase in AML1-MTG8 transcripts level in two patients 2 and 4 months before clinical relapse.
|
8916934 |
1996 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Thus, the presence of AML1/ETO in this case appeared to be due to persistence of the mutated clone as mature myeloid cells instead of MRD, implying that the t(8;21) had occurred in a preleukemic myeloid progenitor cell capable of differentiation.
|
8640725 |
1996 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We have developed a titration assay using a competitive reverse transcriptase polymerase chain reaction (RT-PCR) which is able to estimate the number of AML1/ETO transcripts so that minimal residual disease (MRD) can be monitored quantitatively in patients with t(8;21) acute myelogenous leukaemia (AML).
|
7577620 |
1995 |
Neoplasm, Residual
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Simultaneous monitoring of MRD by RT-PCR using primers for specific DNA markers in 3 patients (2 AML-M3 with PML/RAR alpha, and 1 AML-M2 with AML1/ETO) among these 9 patients detected MRD comparable with that obtained from quantitation of WT1 gene expression.
|
7949179 |
1994 |